MNK,mTOR或eIF4E-选择最好的抗瘤点来阻止翻译启动
Shuo Li1, Jia-Shu Chen1, Xiangqian Li1
1State Key Laboratory of Microbial Technology, Shandong University, Qingdao, 266237, Shandong, PR China.
European journal of medicinal chemistry
|September 5, 2023
概括
针对MNK激酶 (MKNK) 和真核细胞启动因子4E (eIF4E) 抑制剂的转化启动,与mTOR抑制剂相比,显示出优越的抗癌潜力,特别是在固体瘤和血液癌症中.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 细胞启动因子4E (eIF4E) 的过度表达在各种固体瘤和血液癌症中普遍存在,使其成为一种重要的抗癌点.
- 针对调节eIF4E的mTOR激酶和MNK激酶的抑制剂的开发正在迅速推进.
研究的目的:
- 为了比较针对MNK,mTOR和eIF4E的抗癌疗效.
- 通过分析抑制剂特性来确定癌症治疗中最有前途的治疗策略.
主要方法:
- 对针对MNK,mTOR和eIF4E的化合物的抗癌活性进行审查和分类.
- 描述双目标抑制剂的结构和活动.
- 对不同抑制剂特性进行比较分析.
主要成果:
- 与mTOR抑制剂相比,MNK1/2抑制剂和eIF4E/eIF4G相互作用的抑制剂表现出更高的抗癌活性.
- 双位抑制剂显示出增强治疗结果的潜力.
结论:
- 针对MNK1/2和eIF4E/eIF4G相互作用的抑制剂比mTOR抑制剂更有效.
- 同时抑制MNK和eIF4E/eIF4G相互作用是针对癌症治疗中翻译启动的非常有前途的策略.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Initiation of Translation
34.1K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
34.1K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


